# Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years

> **NCT00250640** · — · COMPLETED · sponsor: **Bayer** · enrollment: 106 (actual)

## Conditions studied

- Hypertension, Pulmonary

## Interventions

- **DRUG:** Iloprost (Ventavis, BAYQ6256)

## Key facts

- **NCT ID:** NCT00250640
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2012-04
- **Final completion:** 2012-07
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2015-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00250640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00250640, "Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00250640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*